COMPOUND PROFILE / PEPTIDES & ANALOGUES
Melanotan I / Afamelanotide.
Research draftAfamelanotide is a melanocortin analogue; Melanotan I is a related market label requiring formulation checks.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Identity and evidence review notes
Confirm exact identity, sequence, alias or formulation before attaching product-specific evidence.
Overview
Afamelanotide is a melanocortin analogue; Melanotan I is a related market label requiring formulation checks.
Mechanism
It activates pigmentation-related melanocortin signalling.
Human research
Clinical evidence for the regulated implant concerns erythropoietic protoporphyria. It does not validate injectable tanning products.
Preclinical & other research
Pigmentation studies provide biological rationale, not general skin-protection guarantees.
Safety & unknowns
Pigmented-lesion monitoring and product-specific adverse effects matter.
Regulatory status
US Scenesse is an approved implant for a defined indication. Implant evidence cannot be transferred to unregulated injections.
Reported use & evidence
The supplied Melanotan I / Afamelanotide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.